A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies

Trial Profile

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs RGX 104 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Rgenix
  • Most Recent Events

    • 30 Oct 2017 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 29 Oct 2017 According to a company media release, Rgenix plans to enroll subsequent dose-escalation cohorts of the RGX-104 monotherapy trial in Q4 2017. Additionally, Rgenix is planning to initiate the Phase 1b expansion component of the study, comprised of disease directed cohorts receiving RGX-104 monotherapy as well as cohorts receiving RGX-104 combined with a checkpoint inhibitor, projected to begin in 1H 2018.
    • 29 Oct 2017 Preliminary results (n 15) presented in a Rgenix, Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top